• Oral upadacitinib monotherapy significantly improves eczema severity

    2 monthes ago - By Healio

    Upadacitinib reduced all clinical disease measures including itch-related outcomes at 16 weeks in patients with moderate to severe atopic dermatitis, according to phase 2b study results published in Journal of Allergy and Clinical Immunology.
    “This is a JAK inhibitor that achieved an Eczema Area and Severity Index of 90% improvement in 50% of the patients,” Emma Guttman-Yassky, MD, PhD, of the department of dermatology and laboratory of inflammatory skin diseases at Icahn School of Medicine at Mount Sinai, told Healio in an interview. “This is one of the best rates we have
    Read more ...